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Introduction
The incidence of intrahepatic cholangiocarcinoma (ICC) is
reported to be 4.4 % of all primary liver tumors; it is the
second most common type after hepatocellular carcinoma,
and the 5-year survival rates are 12.2 % for non-surgical cases
and 31.3% for cases that were treated surgically [1]. However,
the intraductal growth type of ICC shows different character-
istics, with the tumor developing very slowly, providing a
better prognosis [2]. We herein describe a case of ICC that
was curatively resected after a 5-year observation. This case
report is particularly interesting because it improves our gen-
eral understanding of a subtype of ICC.
Case Report
A 71-year-old male underwent distal gastrectomy for gastric
cancer of T3N2M0, stage IIIA according to the AJCC/UICC
pathological staging system [3] at another hospital in 2002. He
had received periodic CT examinations every 6 months as
surveillance after surgery. In June 2006, 4 years after the sur-
gery, a mass lesion measuring less than 1 cm in diameter was
found at Couinaud’s hepatic segment 5 (S5) in the liver.
Thereafter, a CT examination was performed every 3 months
to provide a more careful observation of the lesion. The shape
of the tumor gradually changed from round to tubular, and the
mass lesion temporarily decreased in size. During the first
3 years of the observation period, the size of the mass lesion
remained relatively unchanged (Fig. 3). None of the serum
tumor marker levels were elevated after the mass lesion was
detected in the liver. The patient did not receive any chemo-
therapeutic agents during the observation period.
In August 2009, the patient visited our hospital due to new
onset of epigastralgia. He was referred to our surgical depart-
ment because of an abnormality found by an abdominal en-
hanced CT examination.
The patient weighed 53.0 kg, with a height of 145.6 cm,
and showed no abnormalities in the physical examinations
except for a surgical scar on the upper abdomen. His labora-
tory data on admission showed a slightly low hemoglobin
(Hb) level of 12.9 g/dl and slightly elevated alkaline phospha-
tase (ALP) level of 387 U/ml; however, the other data were
nearly within the normal ranges. The levels of tumor markers
such as carcinoembryonic antigen (CEA), carbohydrate anti-
gen (CA) 19-9, α-fetoprotein (AFP), and protein induced by
vitamin K absence or antagonist (PIVKA)II were within the
normal limits.
Abdominal contrast CT scans taken upon admission
showed a tubular mass lesion along the Glisson’s sheath at
S5 as a low density area. The border of the mass lesion was
unclear and it was enhanced gradually from the early to late
phases. The normal part of the liver surrounding the mass
lesion was enhanced by the A-P shunt, and slight atrophy of
the right lobe of the liver was seen (Fig. 1). Abdominal con-
trast MRI also showed the tubular lesion at S5, which ap-
peared to be in the dilated bile ducts. The intensity of the
center of the mass lesion was slightly high in T1W1 and
equivalent in T2W1, and the edge of the mass lesion was
low in T1W1 and slightly high in T2W1 (Fig. 2). According
to the above findings, we considered that the mass lesion in
the liver was likely to be a benign tumor, such as an
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inflammatory pseudotumor or a tumor formed due to some
injury sustained during the previous operation, rather than
primary or metastatic liver cancer. We advised the patient to
undergo a needle biopsy or surgical resection to confirm the
pathological diagnosis; however, he declined to undergo such
an invasive examination. Therefore, careful observation was
continued as had been performed at the previous hospital.
However, after 2 years had passed, the low density mass lesion
gradually increased in size. In July 2011, the size of the mass
lesion reached 3 cm, and an atrophic change of the right lobe
was observed (Fig. 3).
After obtaining informed consent from the patient, we
performed right hepatic lobectomy under the preoperative
diagnosis of suspected ICC. The pathological examination
of the excised specimen revealed that the mass lesion was
cholangiocellular carcinoma (moderately differentiated
adenocarcinoma) at S5/6 of the liver, and the tumor cells
had spread along the bile duct of B5 similar to a tumor
thrombus (Figs. 4 and 5). The final diagnosis according to
the General Rules for the Clinical and Pathological Study
of Primary Liver Cancer [4] was as follows: intrahepatic
cholangiocarcinoma, mass-forming plus intraductal
growth type, moderately differentiated adenocarcinoma;
H2, St-AP, 3.0 cm, ig, fc(−), sf(−), s0, nX, vp1, vv0, b2,
IM0, SM(−), NL.
The patient had an uneventful postoperative course and
was discharged on the 17th day after the operation. We ad-
vised the patient to undergo adjuvant chemotherapy; however,
he refused. The patient has shown no signs of recurrence
24 months after liver surgery.
Fig. 1 Abdominal contrast CT
images of the liver tumor at the
initial visit to our hospital in
August 2009. a Arterial phase. b
Portal phase. c Equilibrium phase
Fig. 2 Abdominal contrast MRI images of the liver tumor at the initial visit to our hospital in August 2009. a T1W1. b T2W2. c Dynamic study
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Discussion
We herein described a case of ICC that was curatively resected
after 5 years of observation. To the best of our knowledge,
there is no previous report of curatively resected ICC after
such a long-term strict observation.
According to the World Health Organization (WHO) clas-
sification of tumors, ICC is defined as an intrahepatic malig-
nant tumor composed of cells resembling those of the bile
duct. ICC arises from any portion of the intrahepatic bile duct
epithelium, such as the intrahepatic large bile duct or
intrahepatic small bile duct. Cholangiocarcinoma arising from
the right and left main hepatic ducts or their junction is referred
to as hilar cholangiocarcinoma [5]. According to the General
Rules for the Clinical and Pathological Study of Primary Liver
Cancer, ICC is classified into three types: the mass-forming
(MF) type, periductal infiltrating (PI) type, and intraductal
growth (IG) type [4]. This classification is also mentioned in
the WHO Classification of Tumors [5] and is now used all
over the world. Although this classification is based on mac-
roscopic findings, it is also related to the pathological features
and prognosis of the tumors. Among the three types, the IG
type spreads only in the bile duct lumen, with less lymph node
and liver metastasis, thus leading to a better prognosis [2].
According to progressive features, two distinct neoplastic
lesions have been identified thus far [6]. One is a flat or
micropapillary growth of atypical biliary epithelium, referred
to as biliary intraepithelial neoplasia (BilIN), which is known
as one of the precursor lesions of ICC according to theWHO’s
Classification of Tumors [5]. The other is an intraductal pap-
illary neoplasm of the bile duct (IPN-B) with malignant po-
tential, which is histologically characterized by the prominent
papillary growth of atypical biliary epithelium with distinct
fibrovascular cores and frequent mucin overproduction [7,
8]. IPN-B is considered to be a counterpart of the intraductal
mucinous neoplasm of the pancreas (IPMN-P) because they
have similar features, such as a macroscopic growth pattern of
intraductal papillary proliferation [9], potential progression to
Fig. 3 The changes in the CT images during the 5 years of observation. a June 2006. bMay 2007. c July 2008. d Aug 2009. e Oct 2010. f July 2011
Fig. 4 The macroscopic findings of the surgical specimen. a A 3×2 cm
solid mass invading to the liver parenchyma and Glisson’s sheath. b The
intraductal growth of the lesions in the B5 bile duct
Fig. 5 The microscopic findings
of the surgical specimen. a The
mass lesion was moderately
differentiated adenocarcinoma.
H&E, ×100. b The bile duct was
filled with the intraductal growth
lesion. H&E, ×40
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tubular adenocarcinoma and mucinous carcinoma [9], in-
creased expression of gastrointestinal metaplasia [10], and a
favorable prognosis after surgical resection [11].
Although the present case did not have mucin production,
the tumor did gradually increase in size. We speculated that
the tumor in the B5 region might initially have been an
intraductal neoplasm equivalent to BilIN or IPN-B. Subse-
quently, repeated blockage and healing of the peripheral bile
duct might have caused the neoplasm to gain malignant po-
tential gradually, finally contributing to its acquiring the abil-
ity to invade and form the mass lesion outside of the bile duct.
On the other hand, histological examinations of the present
case revealed that the intraductal growth lesion demonstrated
significant neutrophil invasion and tumor necrosis. These
findings were consistent with the finding that the tumor tem-
porarily decreased in size during the observation period. Al-
though the IG type of ICC has a different biological behavior
from the other types of ICC, a further understanding of the
pathological and molecular biological features is required.
Therefore, this case is particularly interesting because it con-
tributes to understanding the IG type of ICC.
In the present case, we considered that surgical resection
should have been performed in the earlier period, because the
mass lesion increased in size, resulting in progressive atrophy
of the right lobe of the liver. In addition, we must continue to
pay attention to recurrent or new lesions in this case, because
the tumor consisted of the IG component, as well as the MF
component.
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